AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for CD27 antigen

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We use our state-of-the-art dedicated workflow for designing focused libraries for protein-protein interfaces.

 Fig. 1. The sreening workflow of Receptor.AI

This process entails comprehensive molecular simulations of the target protein, individually and in complex with essential partner proteins, along with ensemble virtual screening that focuses on conformational mobility in both its free and complex states. Potential binding pockets are considered at the protein-protein interaction interface and in remote allosteric locations to address every conceivable mechanism of action.

Several key aspects differentiate our library:

  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

P26842

UPID:

CD27_HUMAN

Alternative names:

CD27L receptor; T-cell activation antigen CD27; T14; Tumor necrosis factor receptor superfamily member 7

Alternative UPACC:

P26842; B2RDZ0

Background:

The CD27 antigen, known by alternative names such as CD27L receptor, T-cell activation antigen CD27, T14, and Tumor necrosis factor receptor superfamily member 7, plays a pivotal role in the immune system. It functions as a receptor for CD70/CD27L, contributing to the survival of activated T-cells and potentially playing a role in apoptosis through its association with SIVA1.

Therapeutic significance:

CD27 antigen's involvement in Lymphoproliferative syndrome 2, a disorder characterized by a spectrum of immune deficiencies including persistent EBV viremia and hypogammaglobulinemia, underscores its therapeutic significance. Targeting CD27 could offer novel treatment avenues for managing this complex immunodeficiency and its life-threatening complications.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
No Spam. Cancel Anytime.